Argenx (ARGX) 2025 Net Product Sales Rise 90% to $4.2B as First Annual Profit Reached

ARGX presents a compelling fundamental-technical divergence that demands careful dissection. The 90% revenue growth to $4.2B and first annual profit are genuinely transformative milestones that typically trigger institutional mandate unlocks, as many quant and fundamental funds exclude pre-profitability biotechs from eligible universes. However, the 12-month price decline of -13.35% concurrent with accelerating fundamental improvement is a significant red flag — markets are forward-looking and this sustained underperformance implies the street is pricing in competitive erosion in the FcRn inhibitor space (UCB, J&J pipeline threats to Vyvgart franchise). Monthly volatility of only 1.94% for a biotech near multi-year lows signals consolidation, not capitulation — distribution risk remains elevated. The reward/risk setup is asymmetric but not cleanly bullish given persistent technical weakness against a strong fundamental backdrop. ⚡ DEEP SONNET: Accumulate in $718-730 range on confirmed volume expansion above 3-week average; avoid chasing any gap-up opening. Current level is at 5-year support — a breach of $710 negates the thesis entirely. Staged entry preferred: 50% now, 50% on confirmation of $745 reclaim. | TP:9.5% SL:3.2% | 3-5 months for institutional re-rating to materialize; profitability milestone typically takes 2-3 earnings cycles to fully embed in buy-side models | Risk:MEDIUM — The core risk is that a 90% revenue growth figure is already partially discounted given ARGX's trajectory was visible to institutional players, yet the stock still lost 13% over 12 months. Competitive overhang from FcRn class crowding, IRA drug pricing policy risks affecting biologics, and potential concentration risk on a single flagship product (Vyvgart) are structural concerns. Healthcare sector policy volatility in 2025-2026 adds macro overlay risk. Low biotech volatility environment may mask sudden binary events. | Sizing:CONSERVATIVE